BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
Mol Cancer Res
; 14(4): 324-31, 2016 04.
Article
em En
| MEDLINE
| ID: mdl-26792867
ABSTRACT
UNLABELLED Next-generation antiandrogen therapies, such as enzalutamide and abiraterone, have had a profound impact on the management of metastatic castration-resistant prostate cancer (mCRPC). However, mCRPC patients invariably develop resistance to these agents. Here, a series of clonal cell lines were developed from enzalutamide-resistant prostate tumor xenografts to study the molecular mechanism of resistance and test their oncogenic potential under various treatment conditions. Androgen receptor (AR) signaling was maintained in these cell lines, which acquired potential resistance mechanisms, including expression of AR-variant 7 (AR-v7) and glucocorticoid receptor. BET bromodomain inhibitors were shown previously to attenuate AR signaling in mCRPC; here, we demonstrate the efficacy of bromodomain and extraterminal (BET) inhibitors in enzalutamide-resistant prostate cancer models. AR antagonists, enzalutamide, and ARN509 exhibit enhanced prostate tumor growth inhibition when combined with BET inhibitors, JQ1 and OTX015, respectively. Taken together, these data provide a compelling preclinical rationale to combine BET inhibitors with AR antagonists to subvert resistance mechanisms. IMPLICATIONS Therapeutic combinations of BET inhibitors and AR antagonists may enhance the clinical efficacy in the treatment of mCRPC. VISUAL OVERVIEW http//mcr.aacrjournals.org/content/molcanres/14/4/324/F1.large.jpg
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Azepinas
/
Triazóis
/
Receptores Androgênicos
/
Resistencia a Medicamentos Antineoplásicos
/
Antagonistas de Receptores de Andrógenos
/
Neoplasias de Próstata Resistentes à Castração
/
Compostos Heterocíclicos com 3 Anéis
/
Acetanilidas
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article